Foretinib
Names | |
---|---|
Preferred IUPAC name
N1-[3-Fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-N′1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
Other names
XL880; EXEL-2880; GSK1363089; GSK089
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard
|
100.158.129 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C34H34F2N4O6 | |
Molar mass | 632.665 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Foretinib is an experimental drug candidate for the treatment of cancer.
Foretinib is an
vascular endothelial growth factor receptor 2 (VEGFR-2).[5]
See also
- c-Met inhibitors
- Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
- VEGFR inhibitor
- tyrosine-kinase inhibitor
References
- .
- ^ "XL880 (GSK1363089)". Exelixis, Inc.
- ^ "Foretinib". clinicaltrials.gov.
- ^ "Foretinib - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.
- PMID 19808973.